AbbVie came into Wednesday’s earnings report down 13% for the year. It left investors with a better story to tell.
$ABBV (AbbVie) #earnings are out: pic.twitter.com/QYJrrUleUc
— The Earnings Correspondent (@earnings_guy) April 29, 2026
The pharma company reported first-quarter adjusted earnings of $2.65 per share, up from $2.46 a year ago and ahead of the $2.59 Wall Street had penciled in. Revenue came in at $15 billion, a 12% jump from a year earlier, clearing analyst forecasts of $14.72 billion.
ABBV rose 2.5% to $202.63 in premarket trading following the results.
The top-line beat was driven largely by two key therapeutic areas. Immunology revenue grew 16%, while neuroscience posted an even stronger 26% increase.
Skyrizi and Rinvoq continued to do the heavy lifting in immunology. Skyrizi, used to treat arthritis and Crohn’s disease, grew revenue 31% in the quarter. Rinvoq followed with 23% growth.
Those gains helped absorb a 39% decline in Humira revenue. The longtime blockbuster drug is under pressure from biosimilar competitors and its contribution to the portfolio continues to shrink.
AbbVie raised its full-year 2026 adjusted EPS outlook to a range of $14.08 to $14.28, up from the prior range of $13.96 to $14.16. Wall Street’s current consensus sits at $14.12, putting the midpoint of the new range slightly above that mark.
The guidance raise signals management’s confidence in the continued momentum from its immunology and neuroscience lineups.
On a GAAP basis, net income for the quarter came in at $695 million, or $0.39 per share. That compares to $1.29 billion, or $0.72 per share, in the same period a year ago. The year-over-year GAAP decline reflects costs not captured in the adjusted figures.
The stock had been under pressure heading into this print, sitting 13% lower for the year as of Tuesday’s close.
The premarket bounce of 2.5% suggests investors welcomed the beat and the raised outlook, though the stock still has ground to recover.
Skyrizi and Rinvoq are now clearly the engines of AbbVie’s growth story, with their combined performance more than offsetting Humira’s ongoing erosion.
Neuroscience is becoming a more meaningful contributor. The 26% growth rate in that segment points to traction beyond the core immunology franchise.
AbbVie’s adjusted EPS of $2.65 marked the second consecutive quarter of year-over-year growth on that metric, with the prior-year figure of $2.46 now clearly in the rearview.
The company’s raised guidance range of $14.08 to $14.28 in adjusted EPS represents the current full-year target investors and analysts will be benchmarking against through the rest of 2026.
The post AbbVie (ABBV) Stock Rises After Q1 Earnings Beat and Raised 2026 Guidance appeared first on CoinCentral.
